image credit- freepik
China and US based Harbour BioMed has announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.
Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programmes. In return, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs.
Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented, "This collaboration leverages our Harbour Mice® fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential. Furthermore, the collaboration offers the possibility to utilize our established development capabilities to accelerate programs by conducting early clinical trials in China. By uniting the strengths of our platform with Bristol Myers Squibb's expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide."
